Recruiting
Phase 2

NX-5948

Sponsor:

Nurix Therapeutics, Inc.

Code:

NCT07221500

Conditions

Chronic Lymphocytic Leukemia (CLL)

Small Lymphocytic Lymphoma (SLL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NX-5948

Study Details

Brief summary:

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.

Conditions

Chronic Lymphocytic Leukemia (CLL)

Small Lymphocytic Lymphoma (SLL)

Study ID

NCT07221500

Start date

Oct 15, 2025

Status verified date

Aug, 2026

Completion date

Oct, 2030

Anticipated

Primary completion date

Jan, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age: ≥ 18 years
  • Confirmed relapsed/refractory CLL/SLL that meets iwCLL criteria for diagnosis and systemic treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Must have received a covalent BTK inhibitor (BTKi), a non-covalent BTKi, and a BCL-2 inhibitor either in separate lines of therapy or in combination; a line of therapy is considered 2 or more consecutive cycles of a systemic anti-CLL/SLL regimen
  • Participants with SLL must have measurable disease by radiographic assessment
  • Adequate organ and bone marrow function
  • Must sign an informed consent form indicating that he or she understands the purpose of the procedures required for the study and is willing to participate

Exclusion Criteria:

  • Known or suspected prolymphocytic leukemia or Richter's transformation before entering study
  • Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) before planned start of study drug

  • Antibody therapy must stop at least 4 weeks before the first dose of study drug
  • No other systemic anticancer therapy is allowed at the same time as this study; exception: continuation of hormonal therapy for breast and prostate cancer is allowed, if they are not on the list of prohibited concomitant medications in this study
  • Palliative limited-field radiotherapy within 7 days of the first dose of study or broad field radiotherapy within 28 days of first dose of study drug
  • Use of systemic corticosteroids >20 mg/day prednisone or equivalent within the 7 days before start of study drug except for those used as premedication for radio diagnostic contrast
  • Use of systemic immunosuppressive drugs other than systemic corticosteroids within 60 days before the first dose of study drug
  • Previously treated with a BTK degrader
  • Previous chimeric antigen receptor (CAR) T-cell therapy or allogeneic or autologous hematopoietic cell transplant within the past 90 days prior to enrollment
  • Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), stroke, or intracranial hemorrhage within 6 months of planned start of study drug

Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Study Design

Enrollment

100 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: NX-5948

Interventions

NX-5948

Oral dose administered once daily. NX-5948 will be given in continuous 28-day cycles.

Primary outcome measure

  • Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC) [ Time Frame: Up to approximately 5 years ]

Central Contacts and Locations

Central contacts

Additional Site Contact Information

415-417-3418clinicaltrials@nurixtx.com

Locations

City of Hope

Recruiting

Duarte, California, United States, 91010

Cedars-Sinai Medical Center

Recruiting

Los Angeles, California, United States, 90048

Scripps Health

Recruiting

San Diego, California, United States, 92121

Colorado Blood Institute

Recruiting

Denver, Colorado, United States, 80218

University of Miami

Recruiting

Coral Gables, Florida, United States, 33146

Florida Cancer Specialists

Recruiting

Sarasota, Florida, United States, 34232

Fort Wayne Oncology and Hematology

Recruiting

Fort Wayne, Indiana, United States, 46804

Hematology Oncology of Indiana

Recruiting

Indianapolis, Indiana, United States, 46260

University of Iowa

Recruiting

Iowa City, Iowa, United States, 52242

Maryland Oncology Hematology

Recruiting

Silver Spring, Maryland, United States, 20904

Karmanos Cancer Center

Recruiting

Detroit, Michigan, United States, 48201

Duke University

Recruiting

Durham, North Carolina, United States, 27705

Novant Health Cancer Institute

Recruiting

Winston-Salem, North Carolina, United States, 27103

University of Cincinnati

Recruiting

Cincinnati, Ohio, United States, 45221

The Cleveland Clinic Foundation

Recruiting

Cleveland, Ohio, United States, 44195

The Ohio State University

Recruiting

Columbus, Ohio, United States, 43210

Oncology Hematology Care

Recruiting

Fairfield, Ohio, United States, 45014

UPMC Hillman Cancer Center

Recruiting

Pittsburgh, Pennsylvania, United States, 15232

SCRI Oncology Partners

Recruiting

Nashville, Tennessee, United States, 37203

Texas Oncology - Center South

Recruiting

Austin, Texas, United States, 78705

University of Utah

Recruiting

Salt Lake City, Utah, United States, 84112

Virginia Cancer Specialists, PC

Recruiting

Fairfax, Virginia, United States, 22031

Oncology & Hematology Associates of Southwest VA

Recruiting

Norfolk, Virginia, United States, 23502

Virginia Oncology Associates

Recruiting

Norfolk, Virginia, United States, 23502

Fred Hutchinson Cancer Center

Recruiting

Seattle, Washington, United States, 98109

More Information

Sponsor

Nurix Therapeutics, Inc.

Last update posted

Aug 19, 2026

Last verified

Aug, 2026

Keywords

  • BTK Degrader
  • BTK Inhibitor
  • BCL-2 Inhibitor
  • B-cell Malignancy
  • Lymphoma
  • Bruton's Tyrosine Kinase
  • NX-5948
  • Targeted Protein Degradation
  • Chimeric Targeting Molecule (CTM)
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Nurix Therapeutics, Inc. on 2026-08-19.